A recent study indicates that measuring apolipoprotein B (apoB) could offer a more precise evaluation of cardiovascular risk than traditional cholesterol metrics like LDL or non-HDL cholesterol. Researchers argue that treatment strategies based on apoB levels might lead to a reduced incidence of heart attacks and strokes over a person’s lifetime compared to current standard methods. Although not widely adopted in regular practice yet, apoB testing seems to be both more effective and cost-efficient than standard cholesterol tests.
- Measuring apoB levels may provide a better assessment of cardiovascular risk than traditional markers.
- Guiding treatment strategies with apoB levels could help reduce heart attacks and strokes compared to existing approaches.
- The study emphasizes apoB testing’s efficiency, even though it is not yet commonplace in clinical practice.
Currently, routine cholesterol tests often include a lipid panel that evaluates total cholesterol levels, aiding in assessing heart disease and stroke risk. This information helps clinicians determine if a patient might need to start statin therapy.
While monitoring cholesterol levels assists in treatment decisions, these tests may not paint a complete picture of a patient’s risk level.
However, in a study published in JAMA, it’s suggested that the less commonly utilized blood marker, apoB, could serve as both a more accurate and cost-effective alternative for guiding treatment decisions, potentially preventing more cardiovascular incidents than current methods.
Traditional cholesterol measures do not provide a direct count of harmful cholesterol particles in the blood. In contrast, apoB is a key component of “bad cholesterol” and might serve as a more accurate indicator of cardiovascular risk compared to standard tests.
Lead study author Ciaran Kohli-Lynch, PhD, assistant professor at Northwestern University Feinberg School of Medicine, explained that for years, LDL cholesterol has been the go-to metric for assessing the effectiveness of cholesterol-lowering medications.
Doctors often consider patients whose LDL levels stay above 100 mg/dL for more intensive treatments. Non-HDL levels are also analyzed since they capture a broader range of harmful particles.
“While these measures are useful, research strongly shows that apoB is better at identifying who is at risk because it counts the total number of harmful particles in the blood,” says Kohli-Lynch.
Kohli-Lynch added that the public health impact of adopting apoB goals to enhance cholesterol-reducing treatment could be significant.
“Using an apoB goal led to substantially fewer heart attacks and strokes in our modeling compared to LDL and non-HDL targets,” he noted.
Yet, he pointed out, the analysis was narrow in scope, focusing only on the role of apoB in those already eligible for cholesterol-lowering medications.
Despite accumulating evidence, apoB testing remains absent from standard cholesterol panels. The research team believes hurdles include the costs and convenience of additional blood tests, with some doctors possibly unaware of apoB testing or insurance not covering it.
Kohli-Lynch elaborated on why apoB hasn’t been widely implemented yet, pointing out that LDL cholesterol has been the traditional measure for years, and shifting established practices can take time.
Moreover, since apoB is not part of standard panels, ordering this test can require extra steps and costs.
The 2026 multi-society dyslipidemia guidelines now recognize apoB as potentially more reflective of cardiovascular risk and endorse its inclusion in clinical practice, albeit not as the primary goal for treatment intensification.
Current guidelines recommend testing apoB levels in individuals with high triglycerides, metabolic syndrome, or type 2 diabetes, which might lead clinicians to continue relying on traditional cholesterol measures.
Researchers from Northwestern University utilized a comprehensive simulation model that involved 250,000 adults eligible for cholesterol-lowering therapy but without cardiovascular disease.
The study compared treatment guidance strategies based on LDL cholesterol, non-HDL cholesterol, and apoB targets.
Participants whose levels surpassed set targets were given increasingly intensive treatments.
Kohli-Lynch emphasized that this research is the first extensive study evidencing that apoB-guided care is both more effective and cost-efficient.
“Prior studies have focused on clinical accuracy rather than the cost-effectiveness of using apoB in guiding treatment,” he noted.
“Cost-effectiveness analysis is crucial information for healthcare payers aiming to allocate resources effectively,” Kohli-Lynch remarked.
Cardiovascular diseases are the leading global cause of death, with cholesterol levels being a major modifiable risk factor for heart disease. Therefore, accurately identifying individuals who would benefit from cholesterol treatment is vital.
The findings coincide with evolving clinical guidelines advocating for earlier and more aggressive cholesterol management, highlighting the need for precise risk assessment.
By improving the identification of high-risk patients, apoB testing could enable more effective treatment targeting, potentially saving lives and reducing unnecessary healthcare expenditures.
“ApoB goals for therapy can enhance cardiovascular outcomes in a clinically meaningful and cost-effective way,” Kohli-Lynch concluded.
While further real-world application and guideline updates are needed, this study bolsters the evidence suggesting that apoB may provide a superior measure of cardiovascular risk in comparison to conventional cholesterol assessments.
